Advertisement

Definition of Target Volume and Organs at Risk. Biological Target Volume

  • Anca-Ligia Grosu
  • Lisa D. Sprague
  • Michael Molls
Part of the Medical Radiology book series (MEDRAD)

13.5 Conclusion

Target volume definition is an interactive process. Based on radiological (and biological) imaging, the radiation oncologist has to outline the GTV, CTV, ITV, and PTV and BTV. In this process, a lot of medical and technological aspects have to be considered. The criteria for GTV, CTV, etc. definition are often not exactly standardised, and this leads, in many cases to variability between clinicians; however, exactly defined imaging criteria, imaging with high sensitivity and specificity for tumour tissue and special training could lead to a higher consensus in target volume delineation and, consequently, to lower differences between clinicians. It must be emphasised, however, that further verification studies and cost-benefit analyses are needed before biological target definition can become a stably integrated part of target volume definition.

The ICRU report 50 from 1993 and the ICRU report 62 from 1999 defining the anatomically based terms CTV, GTV and PTV must still be considered as the gold standard in radiation treatment planning; however, further advances in technology concerning signal resolution and development of new tracers with higher sensitivity and specificity will induce a shift of paradigms away from the anatomically based target volume definition towards biologically based treatment strategies. New concept and treatment strategies should be defined based on these new investigation methods, and the standards in radiation treatment planning — in a continuous, evolutionary process — will have to integrate new imaging methods in an attempt to finally achieve the ultimate goal of cancer cure.

Keywords

Positron Emission Tomography Target Volume Planning Target Volume Radiat Oncol Biol Phys Gross Target Volume 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Belhocine T, Steinmetz N, Li C et al. (2004) The imaging of apoptosis with the radiolabeled annexin V: optimal timing for clinical feasibility. Technol Cancer Res Treat 3:23–32PubMedGoogle Scholar
  2. Bradley J, Thorstad WL, Mutic S et al. (2004) Impact of FDG-PET on radiation therapy volume delineation in NSCLC. Int J Radiat Oncol Biol Phys 59:78–86PubMedCrossRefGoogle Scholar
  3. Chao KS, Bosch WR, Mutic S et al. (2001) A novel approach to overcome hypoxic tumour resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49:1171–1182PubMedGoogle Scholar
  4. Chapman JD, Bradley JD, Eary JF et al. (2003) Molecular (functional) imaging for radiotherapy applications: an RTOG symposium. Int J Radiat Oncol Biol Phys 55:294–301PubMedCrossRefGoogle Scholar
  5. Choi NC, Fischman AJ, Niemierko A et al. (2002) Doseresponse relationship between probability of pathologic tumour control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54:1024–1035PubMedGoogle Scholar
  6. Ciernik IF, Dizendorf E, Baumert BG et al. (2003) Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 57:853–863PubMedCrossRefGoogle Scholar
  7. Coakley FV, Kurhanewicz J, Lu Y et al. (2002) Prostate cancer tumour volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 223:91–97PubMedGoogle Scholar
  8. Dehdashti F, Grigsby PW, Mintun MA et al. (2003) Assessing tumour hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response: a preliminary report. Int J Radiat Oncol Biol Phys 55:1233–1238PubMedCrossRefGoogle Scholar
  9. Erdi YE, Rosenzweig K, Erdi AK et al. (2002) Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 62:51–60PubMedCrossRefGoogle Scholar
  10. Flamen P, Van Cutsem E, Lerut A et al. (2002) Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13:361–368PubMedCrossRefGoogle Scholar
  11. Giraud P, Grahek D, Montravers F et al. (2001) CT and (18)Fdeoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys 49:1249–1257PubMedCrossRefGoogle Scholar
  12. Graves EE, Nelson SJ, Vigneron DB et al. (2000) A preliminary study of the prognostic value of proton magnetic resonance spectroscopic imaging in gamma knife radiosurgery of recurrent malignant gliomas. Neurosurgery 46:319–326PubMedGoogle Scholar
  13. Grigsby PW, Siegel BA, Dehdashti F et al. (2003) Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys 55:907–913PubMedCrossRefGoogle Scholar
  14. Gross MW, Weber WA, Feldmann HJ et al. (1998) The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys 41:989–995PubMedCrossRefGoogle Scholar
  15. Grosu AL, Weber WA, Feldmann HJ et al. (2000) First experience with I-123-Alpha-Methyl-Tyrosine SPECT in the 3-D radiation treatment planning of brain gliomas. Int J Radiat Oncol Biol Phys 47:517–527PubMedCrossRefGoogle Scholar
  16. Grosu AL, Feldmann HJ, Dick S et al. (2002) Implications of IMT-SPECT for postoperative radiation treatment planning in patients with gliomas. Int J Radiat Oncol Biol Phys 54:842–854PubMedGoogle Scholar
  17. Grosu AL, Lachner R, Wiedenmann N et al. (2003) Validation of a method for automatic fusion of CT-and Cll-methionine-PET datasets of the brain for stereotactic radiotherapy using a LINAC. First clinical experience. Int J Radiat Oncol Biol Phys 56:1450–1463PubMedCrossRefGoogle Scholar
  18. Grosu AL, Weber AW, Riedel E et al. (2005a) L-(Methyl-11C) methionine positron emission tomography for target delineation in resected high grade gliomas before radiation therapy. Int J Radiat Oncol Biol Phys 63:64–74PubMedGoogle Scholar
  19. Grosu AL, Weber WA, Franz M et al. (2005b) Re-irradiation of recurrent high grade gliomas using amino-acids-PET(SPECT)/CT/MRI image fusion to determine gross tumour volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys (in press)Google Scholar
  20. Grosu AL, Piert M, Weber WA et al. (2005c) Positron emission tomography in target volume definition for radiation treatment planning. Strahlenther Onkol 181:483–499PubMedCrossRefGoogle Scholar
  21. Haubner R, Wester HJ, Weber WA et al. (2001) Noninvasive imaging of alpha(v)beta3 integrin expression using 18Flabeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61:1781–1785PubMedGoogle Scholar
  22. Hebert ME, Lowe VJ, Hoffman JM et al. (1996) Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. Am J Clin Oncol 19:416–421PubMedCrossRefGoogle Scholar
  23. ICRU 50 (1993) Prescribing, recording and reporting photon beam therapy. ICRU report no. 50. ICRU, Bethesda, MarylandGoogle Scholar
  24. ICRU 62 (1999) Prescribing, recording and reporting photon beam therapy. ICRU report no. 62 (supplement to ICRU report no. 50). ICRU, Bethesda, MarylandGoogle Scholar
  25. Jackson A, Kutcher GJ (1993) Probability of radiation-induced complications for normal tissue with parallel architecture subject to non-uniform irradiation. Med Phys 20:621–625Google Scholar
  26. Julow J, Major T, Emri M et al. (2000) The application of image fusion in stereotactic brachytherapy of brain tumours. Acta Neurochir (Wien) 142:1253–1258CrossRefGoogle Scholar
  27. Källmann P, Ägren A, Brahme A (1992) Tumour and normal tissue responses to fractionated nonuniform dose delivery. Int J Radiat Oncol Biol Phys 62:249–262Google Scholar
  28. Kiffer JD, Berlangieri SU, Scott AM et al. (1998) The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 19:167–177PubMedCrossRefGoogle Scholar
  29. Ling CC, Humm J, Larson S et al. (2000) Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 47:551–560PubMedCrossRefGoogle Scholar
  30. MacManus MP, Hicks RJ, Ball DL et al. (2001) F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 92:886–895Google Scholar
  31. MacManus MP, Hicks RJ, Matthews JP et al. (2003) Positron emission tomography is superior to computed tomography scanning for response assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21:1285–1292Google Scholar
  32. Mah K, Caldwell CB, Ung YC et al. (2002) The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined nonsmall-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 52:339–350PubMedCrossRefGoogle Scholar
  33. Mizowaki T, Cohen GN, Fung AY et al. (2002) Towards integrating functional imaging in the treatment of prostate cancer with radiation: the registration of the MR spectroscopy imaging to ultrasound/CT images and its implementation in treatment planning. Int J Radiat Oncol Biol Phys 54:1558–1564PubMedGoogle Scholar
  34. Molls M (2001) Tumor oxygenation and treatment outcome. In: Bokemeyer C, Ludwig H (eds) ESO scientific updates, vol 6: Anemia in cancer. Elsevier, Amsterdam, pp 175–187Google Scholar
  35. Molls M, Vaupel P (2000) The impact of the tumor environment on experimental and clinical radiation oncology and other therapeutic modalities. In: Molls M, Vaupel P (eds) Blood perfusion and microenvironment of human tumors: implications for clinical radiooncology. Springer, Berlin Heidelberg New York, pp 1–3Google Scholar
  36. Mueller-Lisse UG, Vigneron DB, Hricak H et al. (2001) Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology 221:380–390PubMedGoogle Scholar
  37. Munley MT, Marks LB, Scarfone C et al. (1999) Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer 23:105–114PubMedCrossRefGoogle Scholar
  38. Nestle U et al. (1999) 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 44(3):593–7.PubMedCrossRefGoogle Scholar
  39. Nishioka T, Shiga T, Shirato H et al. (2002) Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys 53:1051–1057PubMedCrossRefGoogle Scholar
  40. Nuutinen J, Sonninen P, Lehikoinen P et al. (2000) Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 48:43–52PubMedCrossRefGoogle Scholar
  41. Pirzkall A, McKnight TR, Graves EE et al. (2001) MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys 50:915–928PubMedCrossRefGoogle Scholar
  42. Pirzkall A, Li X, Oh J et al. (2004) 3D MRSI for resected highgrade gliomas before RT: tumour extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys 59:126–137PubMedCrossRefGoogle Scholar
  43. Rahn AN, Baum RP, Adamietz IA et al. (1998) Value of 18F fluorodeoxyglucose positron emission tomography in radiotherapy planning of head-neck tumours. Strahlenther Onkol 174:358–364 [in German]PubMedCrossRefGoogle Scholar
  44. Rischin D, Peters L, Hicks R et al. (2001) Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 19:535–542PubMedGoogle Scholar
  45. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG et al. (2000) The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother OncolGoogle Scholar
  46. Voges J, Herholz K, Holzer T et al. (1997) 11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125-I seeds. Stereotact Funct Neurosurg 69:129–135PubMedGoogle Scholar
  47. Wagner M, Seitz U, Buck A et al. (2003) 3′-[18F]fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 63:2681–2687PubMedGoogle Scholar
  48. Weber WA, Petersen V, Schmidt B et al. (2003) Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21:2651–2657PubMedGoogle Scholar
  49. Wefer AE, Hricak H, Vigneron DB et al. (2000) Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 164:400–404PubMedCrossRefGoogle Scholar
  50. Zaider M, Zelefsky MJ, Lee EK et al. (2000) Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 47:1085–1096PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • Anca-Ligia Grosu
    • 1
  • Lisa D. Sprague
    • 1
  • Michael Molls
    • 1
  1. 1.Department of Radiation Oncology, Klinikum rechts der IsarTechnical University MunichMunichGermany

Personalised recommendations